Abstract  
Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine (4-AP) in persons with Guillain-Barré Syndrome (GBS) >6 months from initial diagnosis.

Design: A randomized, double-blind, placebo-controlled, crossover study.

Setting: Tertiary care clinical outpatient program.

Participants: Nineteen participants enrolled (14 male, 5 female; N=19), neurologic impairment secondary to GBS and functional loss on the FIM motor score (stable for ≥12mo) and >3.0 but <5.0 on the American Spinal Injury motor scale. Twelve participants (mean age, 59y; range, 23-77y) completed the study.

Interventions: A 4-AP dose-escalation study with 8 weeks in each period with a 3-week washout period, followed by 3 months open-label follow-up.

Main Outcome Measures: FIM motor score was the primary outcome measure; also evaluated were the American Spinal Injury motor strength score (all limbs), handheld dynamometer, 6-minute walk test, Medical Outcomes Study 12-Item Short Form, Center for Epidemiological Studies Depression scale, Positive and Negative Affect Schedule, pain, GBS disability scale, Jepsen-Taylor Hand Function Test, Minnesota Manual Dexterity Test and Minnesota Rate of Manipulation Test, Get Up and Go Test, McGill Pain Inventory, Craig Handicap Assessment and Reporting Technique, and participant self-evaluation.

Results: Seven participants discontinued the study prematurely: 3 because of adverse events, 3 because of travel difficulties or relocation, and 1 because of pretreatment laboratory abnormalities. After removing 3 participants with maximum FIM scores, 4-AP arm trended superior to...
Guillain-Barré syndrome (GBS) is an immunopathy associated with an acute, often fulminating, evolution of a demyelinating inflammatory polyradiculoneuropathy. It can affect anyone, regardless of age, sex, or ethnicity. GBS, also known as acute inflammatory demyelinating polyneuropathy, is the most common cause of acute nontraumatic neuromuscular paralysis in developed countries, afflicting approximately 0.4-1.9 cases/100,000 people annually but varying geographically with some areas up to 3.93 cases/100,000. Recent data indicate that up to 80% of patients with GBS have lifelong residual motor complaints, fatigue, and weakness and/or chronic pain.

Early treatment with plasma exchange or intravenous immunoglobulin may lessen the severity of GBS and speed the recovery process. However, there is no approved treatment of any kind for the debilitating fatigue and motor weakness in patients who have not fully recovered from GBS.

4-aminopyridine (4-AP) is a specific blocker of voltage-dependent, fast-activating neuronal potassium channels. 4-AP restores the action potential conduction in damaged, poorly myelinated nerve fibers by increasing the duration and amplitude of the compound action potential. It also directly enhances synaptic transmission at the synapse, thereby restoring conduction in nerves with a conduction block. The mechanism of action is by blocking membrane potassium channels, thereby enhancing the voltage action potential that can extend the effect beyond damaged nodes of Ranvier from segmental demyelination.

4-AP may also improve neuromuscular conduction at the level of the muscle by increasing transmitter release, thereby improving strength similar to the effect that aminopyridines in general have demonstrated in Lambert-Eaton syndrome. Both the restoration of the conduction block and improved synaptic transmission are mechanisms of action that may benefit the functional status in the patient population with chronic GBS.

4-AP is reported to be effective in patients with demyelination of the central nervous system, such as multiple sclerosis (MS) or spinal cord injury. Double-blind trials with 4-AP have demonstrated that patients with MS benefit from long-term administration of 4-AP, particularly regarding motor function and endurance. Clinical studies have demonstrated that 4-AP is associated with decreased pain and/or improved motor function. In 1 randomized, double-blind, placebo-controlled, crossover study involving 70 patients with MS, 4-AP administered for 12 weeks (maximum dose 0.5 mg/kg) was associated with significant improvements in the Kurtzke expanded disability status scale, activities of daily living, and several neurophysiological parameters. In a study involving 31 patients with MS followed for 6-32 months, ambulation and fatigue improved in 13 patients and visual function improved in 5 patients. Preliminary findings indicate that 4-AP is also associated with decreased pain in patients with MS. 4-AP has been investigated in the treatment of motor weakness and fatigue in GBS and inflammatory polyneuropathy with preliminary findings that were very encouraging.

After discussions with the Food and Drug Administration (FDA) it was decided another phase II trial should be performed with an emphasis on prescribed safety variables and specified coprimary physiological, functional outcome measures, and suggested secondary measures. Consequently, a follow-up phase IIIB, randomized, double-blind, placebo-controlled, crossover, dose-escalation study was conducted to assess the safety and efficacy of 4-AP in participants with chronic motor and sensory deficits from GBS. This initial study emphasizes safety and investigation of potential efficacy outcome measures.

Methods

This phase IIIB, randomized, double-blind, placebo-controlled, crossover, dose-escalation study of the safety and efficacy of 4-AP in participants with GBS was similar to the phase IIA study, with the following exceptions: (1) double-blind treatment periods extended to 8 weeks; (2) placebo washout period increased to 3 weeks between treatment sequences; (3) inclusion criteria refined; and (4) additional exploratory outcome variables included.

Patients were randomized via a coin toss to determine which intervention was first. The research pharmacy kept all medication logs, and the research pharmacy issued all study medication. The study was performed over 3 years. All providers and coordinators were blinded as to which arm each patient was assigned. Institutional Review Board approval was obtained from the University of Alabama at Birmingham Human Investigation Committee.

Inclusion criteria

Participants were required to meet all of the following criteria: (1) were male or female participants, aged 19-75 years, irrespective of race; (2) were able to and had voluntarily given informed consent before any study-specific procedures; (3) had a neurologic impairment secondary to GBS per National Institutes of Health clinical guidelines, which...
had been stable for at least 12 months; (4) had a motor score that averaged between ≤5.0 but was >3.0 on the American Spinal Injury motor scale for all extremities; (5) were able and willing to comply with the protocol; and (6) and agreed to not change in their outpatient therapy or home exercise programs during enrollment in the study.

Exclusion criteria

Participants were excluded from the study for any of the following: (1) they were pregnant or lactating or a woman of child-bearing potential not using reliable birth control or not surgically sterilized; (2) they had a history of seizures; (3) there was any evidence of upper motor neuron involvement; (4) there was any medical condition, including psychiatric disease, which would interfere with the interpretation of the results; (5) they had a known allergy to pyridine-containing substances; (6) their concomitant medications were at a stable dose/regimen <3 weeks, and/or the concomitant medications were expected to change during the study; (7) they had any history of drug or alcohol abuse within the past year; (8) they received an investigational drug within 30 days before the screening visit; (9) they had taken 4-AP in the past; (10) there was a problematic preexisting pain syndrome before the onset of GBS; (11) they had any history of cardiac abnormality or cardiac arrhythmia; and (12) they used any muscle relaxant or drugs with muscle-relaxant properties or drugs with alpha2-adrenergic receptor–blocking properties.

Treatments

The study was carried out in a university-based outpatient physical medicine and rehabilitation clinic. This was a double-blind crossover study assigned via a coin toss to a treatment sequence (table 1). Placebo capsules were identical in appearance to the 4-AP (5.0 mg) capsules. Double-blind crossover study assigned via a coin toss to a treatment sequence (table 1). Placebo capsules were identical in appearance to the 4-AP (5.0 mg) capsules. Double-blind medication for each participant was code-labeled and individually packaged. The initial dose was 1 (5.0 mg) capsule/d at bedtime. The dosage was increased slowly with a target dose of 10 mg 3 times per day after 2 weeks of treatment, with continued treatment at 30 mg/d for an additional 6 weeks (8wk total). Participants underwent a 3-week placebo washout period before they were crossed over to the second treatment (8wk total).

Investigational medication

Information related to the chemistry and manufacture of tablets, including controls as well as the analysis of 4-AP supplied, are provided in the supplemental appendix S1 (available online only at http://www.archives-pmr.org/). The target dose of 4-AP in this study (30 mg 3 times per day) was based on review of safety and pharmacokinetic data in healthy adults and patients with MS or spinal cord injury.7,8 Dosages of up to a total of 30 mg/d have generally been well tolerated in these populations.11,12,21,22 4-AP has a half-life of about 3.6 hours and is predominantly excreted by the kidney without biotransformation. Oral administration of 4-AP in doses significantly above 30 mg/d resulted in plasma levels in excess of 100 ng/mL.21,24

Efficacy variables

Many of the efficacy variables were chosen after consultation with the United States FDA for the Investigational New Drug permit. The Neurologic Division of the Center for Drug Evaluation and Research of the FDA required the study to have coprimary neurologic variables covering both physiological and functional neurologic outcomes.

Primary physiologic outcome measure: motor strength score

The American Spinal Injury motor score measures the strength of key muscles bilaterally in the upper and lower extremities. It is closely related to the American Spinal Injury Association motor scoring technique that is used throughout the rehabilitation community.25 This motor score scale grades motor strength of selected muscle groups on an integer scale ranging from 0 (paralysis) to 5 (normal).

Primary functional outcome measure: FIM motor

FIM motor (13 items) is a widely used measure of functional independence in rehabilitation and has excellent validity.

Table 1 Treatment schedule

| Table 1 Treatment schedule |
|-----------------------------|
| Period 1 | | Period 2 |
| Days | Sequence A 4-AP | Sequence B | Days | Sequence A | Sequence B 4-AP |
| 1-2 | 5 mg/d | Placebo | Placebo Washout Days 61-82 | 83-84 | Placebo | 5 mg/d |
| 3-4 | 5 mg 2 × /d | Placebo | | 85-86 | Placebo | 5 mg 2 × /d |
| 5-6 | 5 mg 3 × /d | Placebo | | 87-88 | Placebo | 5 mg 3 × /d |
| 7-8 | 5-5-10 mg | Placebo | | 89-90 | Placebo | 5-5-10 mg |
| 9-10 | 5-10-10 mg | Placebo | | 91-92 | Placebo | 5-10-10 mg |
| 11-60 | 10 mg 3 × /d | Placebo | | 93-142 | Placebo | 10 mg 3 × /d |

NOTE. Dose escalation only applied when participants did not exhibit a dose-limiting toxicity defined as a drug-related adverse event severe enough to interfere with the participants’ daily activity. In the event participants experienced such toxicity, they were instructed to reduce the dose to the next lowest dosage level. If dose-limiting toxicity continued to occur, the participants were to be discontinued from the study. The maximum allowable dose of 4 AP was 30 mg/d.

* On clinic visit days, participants were to take their morning dose before coming to the clinic.
and reliability.\textsuperscript{26,27} The FIM score ranges from 1 (total assistance) to 7 (complete independence).

**Secondary outcome measures**

**GBS disability scale**

This scale assesses the extent of patient disability using an integer scale ranging from 0 (healthy) to 6 (dead).\textsuperscript{7}

**Hand-held dynamometer (grip strength)**

The Jamar hand-held dynamometer is a reproducible method for evaluating maximal grip strength.\textsuperscript{28} Participants were evaluated 3 times in each hand with a calibrated Jamar dynamometer\textsuperscript{28} with the highest grip strength recorded.

**Jebsen-Taylor Hand Function Test**

The Jebsen-Taylor Hand Function Test assesses functional endurance of the hands. It is an evaluation method that uses 7 tasks representative of everyday functional activities including handwriting.\textsuperscript{29}

**Minnesota Rate of Manipulation Test and the Minnesota Manual Dexterity Test**

The Minnesota Rate of Manipulation Test and Minnesota Manual Dexterity Test involve repetitive movements of the hands using both the extrinsic and intrinsic muscles of the hands.\textsuperscript{30} Both of these tests use the same equipment and are easy to administer.

**Get Up and Go Test**

The Get Up and Go Test is a measurement of functional mobility and is also useful in following clinical change over time.\textsuperscript{31} This test measured how long it took participants to get up from a standard chair and walk 10 m with turning around. Participants were allowed to use their ambulatory assistive devices for this test.

**6-minute walk test**

The 6-minute walk test is widely used to measure endurance in patients with functional limitations. It is well accepted by patients, is easily implemented, and has good reproducibility.\textsuperscript{32,33} The testing procedure followed the American Thoracic Society guidelines.\textsuperscript{33}

**Pain evaluations: McGill Pain Inventory and visual analog scale**

Participants completed the McGill Pain Inventory questionnaire\textsuperscript{34,35} and the visual analog scale (VAS)\textsuperscript{36} for both intensity and unpleasant dimensions. The VAS measured pain at the time of the interview using a scale ranging from 1 (no pain) to 10 (worst). The McGill Pain Inventory also measured pain at the time of the interview, and as part of the McGill Pain Inventory, participants diagrammed their pain locations. Where separate and distinct pain locations were identified, McGill Pain Inventory and VAS measures were taken for each location separately.

**Depression questionnaires**

Participants completed the Center for Epidemiologic Studies Depression Scale, which is a 20-item scale that was used as a covariate in analyses.\textsuperscript{37,38} Because 4-AP reportedly improves mood, its effect on the Positive and Negative Affect Schedule (PANAS) was also measured.\textsuperscript{39}

**Medical Outcomes Study 12-Item Short Form**

The Medical Outcomes Study 12-Item (MOS-12) is a measurement of persons’ perception of their health status.\textsuperscript{40} It is highly correlated with the Medical Outcomes Study 36-Item Short Form.\textsuperscript{41} The MOS-12 provides 2 summary subscale scores: physical health and the mental health summary score.

**Participant self-evaluation**

Participants recorded whether they had noticed changes in the following areas: bladder, bowel, sexual function, motor function, sensation, energy/stamina, or other. They also rated their satisfaction about the effects of the study medication.

**Safety variables**

Safety was evaluated by examination of adverse events and changes in clinical laboratory values, vital signs, electrocardiograms (ECGs), and nerve conduction studies for changes in conduction velocity.

**Adverse events**

An adverse event was any undesirable event that occurred in a participant during the course of the study (or a reasonable time after study termination), whether or not that event was considered study drug related. Adverse effects associated with oral administration of 4-AP have included mild dizziness, lightheadedness, paresis/dysesthesia, nausea, and mild agitation.\textsuperscript{10,20,22,23,42} Doses >30 mg per day have induced confusional states (disorientation, agitation, anxiety), respiratory distress (dyspnea, hyperventilation), locomotor and balance problems, and epileptiform seizures.\textsuperscript{21,23,24,42} These plasma levels were also associated with seizure activity in some patients with MS.\textsuperscript{10,20,21,23,24,42} Cardiac abnormalities have been reported only with extremely high doses, beyond what is now recommended for treatment.\textsuperscript{42}

**Clinical laboratory tests**

Clinical laboratory evaluations included blood chemistry and hematologic tests and are listed in tables 5 and 6. Women of childbearing potential were given an additional urine pregnancy test during the study. The laboratory evaluations included chemistries of alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, blood urea nitrogen, calcium, chloride, creatinine, lactate dehydrogenase, phosphorus, potassium, sodium, and total protein uric acid. The hematology evaluations included hemocrit, hemoglobin, platelet count, red blood cell count, red blood cell indices, white blood cell count, white blood cell differential, neutrophil count (absolute and %), lymphocyte count (absolute and %), monocyte count (absolute and %), eosinophil count (absolute and %), and basophil count (absolute and %).

**Vital signs**

Heart rate and blood pressure were taken at each clinic visit after the participant had been in a reclining position for 3 minutes. If the participant reported symptoms consistent
with postural hypotension, additional blood pressure measures were taken and recorded in the participant’s data worksheet.

Electrocardiograms
A standard 12-lead ECG was recorded at screening and at weeks 2, 4, and 8 of the first treatment period and at weeks 13, 15, and 19 of the second treatment period to assess for any changes, particularly ST segment duration changes and conduction abnormalities.

Nerve conduction studies
All participants had 2 upper motor (median and ulnar), 2 upper sensory (median and ulnar), 2 lower motor (tibial and peroneal), and 2 lower sensory (peroneal and sural) nerve conduction velocities performed at screening and at week 8 in both arms. In addition, 1 upper and 1 lower F-wave were performed, which assesses for objective improvement in nerve conduction velocity with use of 4-AP. Nerve conduction velocities and amplitudes were performed for the median and peroneal nerves. Particular attention was given to the nerve conduction velocity, the terminal latency, changes in the negative to positive peak duration, and area under the curve. These are accepted parameters for evaluating demyelination using electrodiagnosis.

Statistical and analytical plans
The efficacy analysis was performed on randomized participants who completed both treatment periods. The safety analysis was performed on all participants who received at least 1 dose of study medication (18 participants).

All data were reported as mean ± 1 SE and ± 1 SD. The Wilcoxon signed-rank test was used to test the significance of observed differences between baseline and after 8 weeks of continuous treatment for ordinal measured data (eg, GBS disability scale, motor strength, VAS). We assessed changes over time using Friedman’s analysis, which is the nonparametric equivalent of the repeated measures analysis of variance model. Two-tailed tests were used, with P<.05 considered significant. Although nonparametric tests were used, data are presented as means and SDs to facilitate the interpretation of the magnitude and clinical significance of the results. The physiological motor score was obtained by combining both the upper extremity and lower extremity scores, which were then averaged for motor score. We similarly analyzed the average scores for the Jebsen-Taylor Hand Function Test, 6-minute walk test, GBS disability scale, pain (VAS, McGill, PANAS), Minnesota Manual Dexterity Test, MOS-12, and FIM motor.

All clinical laboratory tests, nerve conduction studies, and grip strength tests were assessed using a 2-tailed Student t test and/or a 1-way analysis of variance model with repeated measures.

Results
Fourteen male and 5 female participants were in the study. The mean age of the study population was 59 years (range, 23-77y). Seven participants discontinued the study prematurely. Three discontinued because of adverse events that were considered likely related to 4-AP: 1 because of tremor, cramping, weakness, dizziness, ataxia, and diabetic hypoglycemia; 1 because of weakness, shaking (tremors), and postural hypotension; and 1 because of dizziness. Two participants discontinued because of travel difficulties and 1 because of relocation. One enrolled participant discontinued because of pretreatment laboratory abnormalities. The remaining 12 participants completed both periods of the crossover study.

Primary Outcomes
Physiologic: motor scores
The mean ± SD baseline motor strength score (all extremities combined) for study participants was 105.08±13.64. The maximum obtainable score on this measure is 120, with higher scores indicating greater muscle strength. Higher mean ± SE motor strength scores were found for placebo 109.6±2.2 compared with 4-AP treatment 107.2±2.2 (table 2). However, a trend toward statistical significance was apparent between 4-AP and placebo (F1,10=3.30, P=.10), although it was not in the desired direction. A ceiling effect on the motor strength scale was apparent for some participants but does not appear clinically meaningful (fig 1).

Function: FIM motor scores
The mean ± SD baseline FIM motor score for all study participants was 83.58±10.80. The maximum score on the FIM motor scale is 91, with higher scores indicating greater functional independence. Table 3 presents the tests for the fixed effects in the model. There was an improvement in the motor scores with 4-AP treatment associated with higher FIM scores than with placebo treatment, indicating greater functional independence, but this fell short of statistical significance (P=.1205) (see table 3A). At the end of 8 weeks,

Table 2  Motor strength score: type 3 tests of fixed effects and means

| Effect      | Degrees of Freedom | F Value | P Value |
|-------------|--------------------|---------|---------|
|             | Numerator          | Denominator |       |       |
| Treatment   | 1                  | 9       | 3.30    | .1026  |

| Effect      | Treatment          | Mean    | SE     | df | t Value | Pr>||t| |
|-------------|--------------------|---------|--------|----|---------|------|
| Treatment   | 4-AP               | 107.18  | 2.2437 | 9  | 47.77   | <.00001 |
| Treatment   | Placebo            | 109.65  | 2.2437 | 9  | 48.87   | <.00001 |

NOTE. Motor score strength scores and statistical evaluation using Wilcoxon signed-rank.
Abbreviation: Pr, P reference value.
the mean FIM score for 4-AP was 85.7 compared with 83.7 for placebo (see table 3B). The group on average, however, tended to have FIM scores near the upper limit at baseline, which produced a “ceiling effect,” that is, reduced the amount of change that can be detected with the FIM. Treatment effects were thus more difficult to detect because of the presence of ceiling effects.

FIM motor data were then examined by individual participant during 4-AP treatment (see table 3B) (fig 2). Fitted ordinary least squares trajectories were superimposed on the empirical response plots for participants in the following series of plots. A ceiling effect was clearly observed in the majority of the participants (see fig 2).

Visual inspection of the case report forms and original electronic database revealed some inconsistencies in FIM scores that could not be reconciled between the 2 sources of information for 1 participant (no. 4). FIM data for this participant were thus removed and the data reanalyzed (see table 3B). This revised analysis still failed to establish a clear improvement in motor function because there was a ceiling effect on the amount of change that could be detected with the FIM.

Table 3 FIM motor scores and statistical evaluation using Wilcoxon signed-rank.

| Table 3A FIM motor: type 3 tests of fixed effects |
|-----------------------------------------------|
| Effect | Degrees of Freedom | F Value | P Value |
| Treatment | 1 | 10 | 2.88 | .1205 |
| FIM motor: means |

| Table 3B FIM motor reanalysis: type 3 tests of fixed effects |
|-----------------------------------------------|
| Effect | Degrees of Freedom | F Value | P Value |
| Treatment | 1 | 9 | 2.48 | .1497 |
| FIM motor reanalysis: means |

| Effect | Treatment | Estimate | SE | df | t Value | Pr>|t| |
| Treatment 4-AP | 85.6667 | 0.7985 | 10 | 107.29 | <0.0001 |
| Treatment Placebo | 83.7500 | 0.7985 | 10 | 104.89 | <0.0001 |

| Effect | Treatment | Estimate | SE | df | t Value | Pr>|t| |
| Treatment 4-AP | 86.76 | 0.8534 | 9 | 101.66 | <0.0001 |
| Treatment Placebo | 84.86 | 0.8534 | 9 | 99.43 | <0.0001 |

NOTE. FIM motor score scores and statistical evaluation using Wilcoxon signed-rank. Abbreviation: Pr, P reference value.
effect for a majority of the participants. This did not improve the results ($P=.1497$), although a positive trend was noted.

**Secondary outcomes**

**Functional**

No statistically significant differences were found between 4-AP and placebo after 8 weeks of treatment for motor strength scores, bilateral grip strength (hand-held dynamometer), 6-minute walk test, MOS-12 physical component summary, Center for Epidemiologic Studies Depression Scale, and PANAS. Overall, there was a good deal of variability in the data, especially in the second treatment sequence (table 4).

**Safety: laboratory and other tests**

The 1 laboratory test that changed while on 4-AP was mean alkaline phosphatase, which increased statistically ($P=.04$), but this was not felt to be clinically important in any 1 patient treated and may be related to enzyme induction. Otherwise there were no other abnormal laboratory values discovered in individual participants, and the average values demonstrated no statistical trends or clinically significant changes throughout the study (tables 5 and 6). Urinalysis tests revealed no changes.

No seizures were reported, nor were there any other clinically significant changes in laboratory tests, vital signs, ECG parameters, or nerve conduction studies in either amplitude or velocity of conduction.

**Discussion**

The primary focus of this phase IIB trial was safety as required by the FDA. In this regard the study demonstrated excellent safety at the prescribed dosing and in the method of reaching the maximal dose. In this second phase IIB trial a trend for improvement of the FIM motor score was observed in this population with GBS, but the results are clearly inconclusive and not clinically meaningful for motor function as the primary outcome. A trend for improvement was observed for some endpoints. There were some indications of a carryover effect of 4-AP, indicating a prolonged neurologic effect long after the drug is cleared from the general systemic circulation of the body, but the design of the study and the small number of participants precludes any conclusions in this area. Those outcome measures that have more

---

**Table 4** Changes from baseline of the efficacy parameter determined in the phase IIB trial

| Parameters                  | Baseline | 4-AP Wk 8 | Placebo Wk 8 | P Value |
|-----------------------------|----------|-----------|--------------|---------|
| Grip strength (right hand)  | 49.4 lb  | 52.5 lb   | 52.4 lb      | .97     |
| Grip strength (left hand)   | 52.6 lb  | 52.3 lb   | 53.0 lb      | .83     |
| 6-minute walk test          | 972 ft   | 1105 ft   | 1105 ft      | .99     |
| MOS-12                      | 30.0 (SD=9.1) | 34.7 (SD=2.2) | 36.3 (SD=2.1) | .59     |
| CES-D                       | 9.4 (SD=9.8) | 7.3 (SD=1.7) | 5.2 (SD=1.7) | .42     |
| PANAS (positive affect)     | 34.0 (SD=5.6) | 36.0 (SE=2.9) | 33.9 (SE=2.9) | .56     |
| PANAS (negative affect)     | 16.8 (SD=5.6) | 12.5 (SE=1.4) | 10.8 (SE=1.4) | .29     |
| Pain (VAS)                  | 4.2 (SD=3.4) | 3.0 (SD=1.2) | 3.1 (SD=1.2) | .92     |

NOTE. Data presented as mean (SE/SD).

Abbreviation: CES-D, Center for Epidemiologic Studies Depression Scale.
of a motor endurance measure appear to demonstrate more meaningful trends.

Similar to the findings with MS, there could be a distinct subgroup of patients with GBS who may benefit from the use of 4-AP for functional skills, either because of timing after illness or because of a specific functional deficit. The effect appears to be more activity based than a general improvement in motor power because the physiological motor scores did not markedly improve vs placebo. This study, along with a previous small study indicate that 4-AP needs further study in specific subgroups of demyelinating diseases.23

Study limitations

This preliminary study combined with a previous small study are limited in numbers because of the parameters of this orphan drug study by the US FDA after discussions. It is likely that because of the small sample size significance was not reached. This is supported by the fact that the variability of data were considerably high because of the diversity of the patient population. Patients with various levels of disability were recruited into the studies.

Table 5  Chemistry: paired change in serum samples test during 4-AP treatment (change from baseline to wk 8)

| Parameters                  | Paired Differences | 95% CI               | t Value | df  | P Value* |
|-----------------------------|--------------------|----------------------|---------|-----|----------|
| Sodium (mEq/L)              | -0.17              | 1.946                | -1.40   | 1.07| -0.297   | 1.772 |
| Potassium (mEq/L)           | 0.000              | 0.4805               | -0.305  | 0.305| 0.000    | 1.1    | >.99  |
| Chloride (mEq/L)            | 0.58               | 2.109                | -0.76   | 1.92 | 0.958    | 1.1    | .359  |
| Calcium (mEq/L)             | 0.175              | 0.2864               | -0.007  | 0.357| 2.116    | 1.1    | .058  |
| Bicarbonate (mEq/L)         | -0.58              | 2.503                | -2.17   | 1.01 | -0.807   | 1.1    | .437  |
| Total protein (mg/dL)       | 0.110              | 0.4748               | -0.230  | 0.450| 0.733    | 1.5    | .482  |
| Glucose (mg/dL)             | 5.09               | 11.987               | -2.96   | 13.14| 1.409    | 1.1    | .189  |
| BUN (mg/dL)                 | 2.33               | 4.271                | -0.38   | 5.05 | 1.892    | 1.1    | .085  |
| Creatinine (mg/dL)          | -0.017             | 0.1467               | -0.110  | 0.077| -0.394   | 1.1    | .701  |
| Uric acid (mg/dL)           | 0.200              | 0.7274               | -0.262  | 0.662| 0.952    | 1.1    | .361  |
| Albumin (g/dL)              | 0.100              | 0.1581               | -0.022  | 0.222| 1.897    | 1.1    | .094  |
| Phosphorus (mg/dL)          | 0.282              | 0.4468               | -0.018  | 0.582| 2.092    | 1.1    | .063  |
| Total bilirubin (mg/dL)      | 0.010              | 0.2998               | -0.204  | 0.224| 0.105    | 1.1    | .918  |
| LDH (U/L)                   | 23.41              | 65.899               | -18.46  | 65.28| 1.230    | 1.1    | .244  |
| AST (U/L)                   | 1.60               | 7.834                | -4.00   | 7.20 | 0.646    | 1.1    | .535  |
| ALT (U/L)                   | 0.60               | 7.877                | -5.03   | 6.23 | 0.241    | 1.1    | .815  |
| ALP (U/L)                   | 3.50               | 4.673                | 0.16    | 6.84 | 2.369    | 1.1    | .042  |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; LDH, lactate dehydrogenase.

* Two-tailed paired Student t test.

Table 6  Hematology: paired samples test during 4-AP treatment (change from baseline to week 8)

| Parameters                  | Paired Differences | 95% CI               | t Value | df  | P Value* |
|-----------------------------|--------------------|----------------------|---------|-----|----------|
| PCV (%)                     | 0.64               | 1.286                | -0.23   | 1.50| 1.641    | 1.1    | .132  |
| Hemoglobin (g/dL)           | 0.136              | 0.6217               | -0.281  | 0.554| 0.727    | 1.1    | .484  |
| RBC count (× 10^6/μL/L)      | 0.0709             | 0.13736              | -0.0214 | 0.1632| 1.712    | 1.1    | .118  |
| Platelet count (× 10^5/μL/L) | -9.236             | 72.4828              | -57.931 | 39.458| -0.423   | 1.1    | .682  |
| WBC count (× 10^3/μL/L)      | -0.1991            | 1.38885              | -1.1321 | 0.7340| -0.475   | 1.1    | .645  |
| WBC differential             |                    |                      |         |     |          |        |       |
| Segments (%)                 | -0.45              | 5.646                | -4.25   | 3.34 | -0.267   | 1.1    | .795  |
| Lymphocytes (%)              | 0.18               | 3.219                | -1.98   | 2.34 | 0.187    | 1.1    | .855  |
| Monocytes (%)                | 0.55               | 2.505                | -1.14   | 2.23 | 0.722    | 1.1    | .487  |
| Eosinophils (%)              | -0.20              | 1.317                | -1.14   | 0.74 | -0.480   | 1.1    | .642  |
| Basophils (%)                | 0.20               | 0.632                | -0.25   | 0.65 | 1.000    | 1.1    | .343  |

Abbreviations: CI, confidence interval; PCV, packed cell volume; RBC, red blood cell; WBC, white blood cell.

* Two-tailed paired Student t test.
the drug. Three patients had to drop out, including 1 because of the changes in sensation, so adverse effects will need to be monitored closely if this goes to a phase III trial, which was recommended by the FDA in the next trial. It does provide some good data regarding the relevant outcome measures the FDA would like explored as well as data that could be used for a larger power analyses for a definitive study (fig 3).

Conclusions

This trial along with a previously reported small trial are the first trials to have been performed to investigate the effects of 4-AP in the therapy of GBS including a control group (see fig 3). This study is inconclusive on the use of 4-AP in patients with chronic functional limitations from GBS several months from the acute occurrence.

There were indications of benefits of 4-AP in GBS because positive trends were also observed for other endpoints in the study. The patient comments indicated they had benefits and additional improvements, but more work would be necessary to define a subpopulation that may benefit, as there was in MS.

Limited adverse effects occurred in our study, mostly associated with mild tremors that abated. Despite the previous report on dysesthesias, this was not a reported problem for this study. However, all the patients felt they could tell when they were on the drug because of tingling and were noted to be all correct after unblinding.

There is significant interest in using this compounded medication in demyelinating diseases. Clearly, this needs to be more carefully studied in humans before any conclusions may be drawn. This study does outline the primary outcome measures and has enough statistical input to estimate power analyses for selected outcome measures for a phase III Investigational New Drug trial.

 Suppliers

a. API; Regis Technologies Inc.
b. Study medication 5.0 mg 4-AP capsules and matching placebo including inactive ingredients of lactose and coloring; Scott Wepfer, RPh, The Compounding Shoppe.
c. Analysis of 4-AP purity and concentration; Analytical Research Labs.
d. Jamar dynamometer; Patterson Medical.

 Corresponding author

Jay M. Meythaler, JD, MD, Department of Physical Medicine and Rehabilitation, Wayne State University School of Medicine, 213 Lande, 550 E Canfield, Detroit, MI 48201. E-mail address: jmeythal@med.wayne.edu.

 References

1. Meythaler JM. Acute and chronic inflammatory demyelinating polyneuropathies. In: Kirshblum S, Lin VW, eds. Spinal cord..
injury medicine, Philadelphia: Lippincott Williams & Wilkins; 2018:584-606.

2. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33.

3. Wijdicks EFM, Klein CJ. Guillain-Barre syndrome. Mayo Clin Proc 2017;92:467-79.

4. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet 2016;388:717-27.

5. Hughes RAC, Wijdicks EFM, Benson E, et al. Supportive care for patients with Guillain-Barre syndrome. Arch Neurol 2005;62:1194-8.

6. Pentland B, Donald SM. Pain in the Guillain-Barré syndrome: a clinical review. Pain 1994;59:15964.

7. Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736.

8. Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2020;1:CD008630.

9. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991;8:1031-9.

10. Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 1993;10:1924.

11. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:2926.

12. van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:12330.

13. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:6037.

14. Kocsis JD, Waxman SG, Hildebrand C, Ruiz JA. Regenerating mammalian nerve fibres: changes in action potential waveform and firing characteristics following blockage of potassium conductance. Proc R Soc Lond B Biol Sci 1982;217:7778.

15. Kocsis JD, Waxman SG. Long-term regenerated nerve fibres retain sensitivity to potassium channel blocking agents. Nature 1983;304:6402.

16. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:4752.

17. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:5702.

18. Targ EF, Kocsis JD. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res 1986;363:19.

19. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parikhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:13448.

20. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, cross-over study in eight patients. J Neurotrauma 1993;10:118.

21. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:81721.

22. Segal JL, Pathak MS, Hernandez JP, Himber PL, Brunnenmann SR, Charter RS. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19:71233.

23. Meythaler JM, Brunner RC. Improvement of motor, sensory, and functional status of post-Guillain-Barre syndrome with the use of 4-aminopyridine. Int J Phys Med Rehabil 2014;2:3.

24. Bever Jr. CT. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994;36(Suppl):S18-21.

25. American Spinal Injury Association. International standards for neurological classification of spinal cord injury. Available at: https://asia-spinalinjury.org/ISNCSCI-2019-revision-released/.

26. ASIA and ISCoS International Standards Committee. The 2019 revision of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCS/C)-What’s new? Spinal Cord 2019;57:815-7.

27. Heinemann AW, Linares JM, Wright BD, Hamilton BB, Granger C. Relationship between impairment and physical disability as measured by the functional independence measure. Arch Phys Med Rehabil 1993;74:56673.

28. Bohannon RW. Hand-grip dynamometry provides a valid indication of upper extremity strength impairment in home care patients. J Hand Ther 1998;11:25860.

29. Jebsen RH, Taylor N, Trieschmann RB, Howard L. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969;50:311-9.

30. Juregensen CE. Extension of the Minnesota Rate of Manipulation Test. J Appl Psychol 1943;27:1649.

31. Jackson AB, Carmel CT, Ditunno JF, et al. Outcome measures for gait and ambulation in the spinal cord injury population. J Spinal Cord Med 2008;31:487-99.

32. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:91923.

33. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:11117.

34. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:27799.

35. Gracely RH. Evaluation of multi-dimensional pain scales. Pain 1992;48:297300.

36. Jensen MP, Karoly P, Braver S. The measurement of pain intensity: a comparison of six methods. Pain 1986;27:11726.

37. Radloff LS. One CES-D scale: a self-report; depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.

38. Phifer JF, Murell SA. Etiologic factors in the onset of depressive symptoms in older adults. J Abnorm Psychol 1986;95:281-91.

39. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:106370.

40. Ware JE, Kosinski M, Keller SD. The 6-minute walk test. Am J Respir Crit Care Med 2002;166:11117.

41. Murray NMF, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:26571.

42. McKhann GM. Guillain-Barre syndrome: clinical and therapeutic observations. Ann Neurol 1990;27(Suppl):S18-21.

43. Olney RK. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999;22(Suppl 8):S2259.

44. Albers JW. AAEM case report #4: Guillain-Barre syndrome. Muscle Nerve 1989;12:705-11.
46. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:18692.

47. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:35362.

48. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502.

49. Tseng KC, Li H, Clark A, et al. 4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury. EMBO Mol Med 2016;8:1409-20.

50. Meythaler JM, Peduzzi-Nelson J. Use of 4-aminopyridine for motor weakness due to Charcot-Marie-Tooth hereditary motor sensory neuropathy. Phys Med Rehabil 2017;1:3-8.

51. Clark AR, Hsu CG, Talukder MAH, Noble M, Elfar JC. Transdermal delivery of 4-aminopyridine accelerates motor functional recovery and improves nerve morphology following sciatic nerve crush injury in mice. Neural Regen Res 2020;15:136-44.

52. Noble M, Tseng KC, Elfar JC. 4-Aminopyridine as a single agent diagnostic and treatment for severe nerve crush injury. Mil Med 2019;184(Suppl 1):379-85.